title: Treatment of Low-Risk Basal Cell Carcinoma.
abstract: With the continuously rising incidence and changing populations of patients with basal cell carcinoma, evidence about the different treatment modalities is mandatory. Randomized clinical trials, such as the surgery versus imiquimod for nodular superficial basal cell carcinoma trial, can provide this evidence. Patients can then be informed about all aspects of alternative treatment options so that conscious, shared decisions can be made.
authors.affiliation: Department of Dermatology, Maastricht University Medical Centre, Maastricht, The Netherlands; GROW, School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands. Electronic address: n.kelleners.smeets@mumc.nl.
authors.forename: Nicole W J
authors.initials: NWJ
authors.lastname: Kelleners-Smeets
authors.affiliation: Department of Dermatology, Maastricht University Medical Centre, Maastricht, The Netherlands; GROW, School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands.
authors.forename: Klara
authors.initials: K
authors.lastname: Mosterd
authors.affiliation: Department of Epidemiology, CAPHRI, School for Public Health and Primary Care, Maastricht University, Maastricht, The Netherlands.
authors.forename: Patty J
authors.initials: PJ
authors.lastname: Nelemans
mesh_terms: D000634:Aminoquinolines; D000970:Antineoplastic Agents; D002280:Basal Cell Carcinoma; D006801:Humans; D012878:Skin Neoplasms; D016896:Treatment Outcome
chemical_list: D000634:Aminoquinolines; D000970:Antineoplastic Agents